Amr Moussa, MD
Nephrology · Cincinnati, OHNPI 1407910771
Payments from drug & device makers
Across 9 payments — averaging $31.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$110
- Medtronic$59
- Fresenius USA Marketing, Inc.$47
- Mallinckrodt Hospital Products Inc.$29
- Ultragenyx Pharmaceutical Inc.$29
- Travere Therapeutics, Inc.$6
What the payments were for
- Food & beverage$27398%
- Education$62%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 1 | $110 |
| Medtronic | 1 | $59 |
| Fresenius USA Marketing, Inc. | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$279 in reported general payments places this provider in the 20th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Labetalol Hcl | 126 | $2,965 |
| Isosorbide Dinitrate | 30 | $2,050 |
| Nifedipine ErNifedipine | 75 | $1,890 |
| Sevelamer Carbonate | 20 | $1,855 |
| Torsemide | 76 | $1,222 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,214 |
| Eplerenone | 13 | $785 |
| Hydralazine Hcl | 74 | $754 |
| Doxazosin Mesylate | 31 | $750 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 36 | $462 |
| Potassium Chloride | 12 | $458 |
| Amlodipine Besylate | 60 | $448 |
| Terazosin Hcl | 15 | $418 |
| Carvedilol | 26 | $404 |
| Losartan Potassium | 44 | $349 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Cincinnati
- Prabir Roy ChaudhuryCincinnati$483K
- Amit GovilCincinnati$444K
- Manish AnandCincinnati$384K
- Kotagal KantCincinnati$334K
- Charuhas ThakarCincinnati$207K
- Suresh KamathCincinnati$159K
- Prakash GudsoorkarCincinnati$124K
- Chebel KhalilCincinnati$72K
- Ahmad AnjakCincinnati$65K
- Arshdeep TindniCincinnati$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.